The incretin class of peptides has generated more mainstream attention than perhaps any other category of research compounds in the past decade. Semaglutide, tirzepatide, and retatrutide — representing mono-agonist, dual-agonist, and triple-agonist approaches respectively — have been studied extensively in clinical trials focused on metabolic function and body composition. This article provides a factual overview of all three compounds, their mechanisms, and how they compare

The incretin peptide class has evolved rapidly. In the span of a few years, metabolic peptide research has progressed from single-receptor compounds to dual-receptor and now triple-receptor agonists. Semaglutide, tirzepatide, and retatrutide represent three generations of this progression — each building on the pharmacological foundation of the last. This article compares all three compounds across their receptor pharmacology, clinical data, and research implications. The Cor

Tirzepatide 10mg dual agonist research peptide vial Durham Peptides Canada If semaglutide represented a breakthrough in GLP-1 receptor agonist research, tirzepatide represents the next evolution — a synthetic peptide that activates two incretin receptors simultaneously. This dual mechanism has generated significant interest among researchers studying metabolic regulation, glucose homeostasis, and body composition. This article covers what tirzepatide is, how its dual agonist

Semaglutide peptide vial from Durham Peptides Canada Semaglutide and tirzepatide are two of the most discussed peptide compounds in modern biomedical research. Both belong to the incretin class of peptides — compounds that mimic or enhance the body's natural gut hormones involved in metabolic regulation. While they share some common ground, their mechanisms of action are fundamentally different, which is why researchers frequently compare them in head-to-head studies. This ar